1 / 12

Inhibition of E xperimental C orneal Neov ascularization by B evacizumab (Avastin)

Inhibition of E xperimental C orneal Neov ascularization by B evacizumab (Avastin). Yonca A. Akova, MD Veysi Öner, MD Cem Küçükerdönmez, MD. Ba s kent University, School of Medicine Department of Ophthalmology, Ankara Turke y.

sienna
Télécharger la présentation

Inhibition of E xperimental C orneal Neov ascularization by B evacizumab (Avastin)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Yonca A. Akova, MD Veysi Öner, MD Cem Küçükerdönmez, MD Baskent University, School ofMedicineDepartment of Ophthalmology, AnkaraTurkey The authors acknowledge no financial interest in the subject matter of this presentation

  2. Purpose To evaluate and compare the inhibitory effects of topical high dose, low-dose and subconjunctival bevacizumab (Avastin, Genentech Inc., San Francisco, Ca, USA) on corneal vascularization in a rat model

  3. Methods • Group 1: Control group that received only topical artificial tear twice daily • Grup 2: Subconjunctival injection group that received 0.05 ml (1.25mg) of bevacizumab on day 1, 4 and 7 • Group 3: Low-dose topical bevacizumab (4mg/ml) group that received twice daily • Group 4: High-dose topical bevacizumab (12.5 mg/ml) group that received twice daily • Corneas of 20 rats (Sprague-Dawley, male) were chemically cauterized with silver nitrate sticks in order to induce neovascularization • Animals were divided in four groups

  4. Methods • Digital photographs of the corneas were taken and analyzed using an image analysis software(Pixcavator Image Analyzer, Intelligent Perception,WV, USA) • On day 10, all animals were sacrificed and the eyes were enucleated • Corneas were excised and examined histopathologically

  5. Results

  6. Topical high-dose bevacizumab group (12.5 mg/ml) Control group

  7. Control group Topical low-dose bevacizumab group (4mg/ml)

  8. Subconjunctival bevacizumab group (1.25mg/0,05ml) Control group

  9. Results • In histological examination of the excised corneas, treated eyes showed significantly less neovascular areas and number of vessels in group 2,3 and 4 than the control group • The differences between control group and treatment groups were found to be statistically significant (p < 0.05 for all) • Bevacizumab is able to inhibit corneal angiogenesis, without any difference of this effect with • Changing the route of administration (subconjunctival or topical) • Increasing the dosage (4mg/ml or 12.5mg/ml for topical form)

  10. Topical low-dose bevacizumab group Control group

  11. Discussion • Both topical and subconjunctival application of bevacizumab reduces experimental corneal vascularization significantly compared to the control group • Clinical use of bevacizumab may have an additional effect in the treatment for corneal neovascularization

  12. NAME: Yonca Aydın Akova, M.D. TITLE: Professor in Ophthalmology DATE AND PLACE OF BIRTH: October 21, 1960, Turkey 1983: Doctor of Medicine, Istanbul University, School of Medicine 1990: Istanbul University, School of Medicine, Department of Ophthalmology 2000:Professor of Ophthalmology, Baskent University, School of Medicine, Department of Ophthalmology, Ankara, Turkey 2002: Chairperson, Baskent University, School of Medicine, Department of Ophthalmology, Ankara, Turkey NAME:, Veysi Öner, M.D. TITLE: Resident in Ophthalmology DATE AND PLACE OF BIRTH: March01, 1979, Turkey 2002: Doctor of Medicine, Hacettepe University, School of Medicine 2003-2008 : Resident, Başkent University, School of Medicine, Department of Ophthalmology, Ankara, Turkey NAME: Cem Küçükerdönmez, M.D. TITLE: Fellow in Ophthalmology DATE AND PLACE OF BIRTH: October9, 1975, Turkey 1999: Doctor of Medicine, Hacettepe University, School of Medicine 2003 : Başkent University, School of Medicine, Department of Ophthalmology

More Related